Bacteriophage Therapy Market Size to Exceed USD 1,776.5 Mn by 2032

The Bacteriophage Therapy Market, estimated at USD 1,377.6 Mn in 2025, is expected to exhibit a CAGR of 3.7% and reach USD 1,776.5 Mn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

Key market players are focusing on adopting growth strategies such as investment funding, which will drive the global bacteriophage therapy market. For instance, in May 2025, Intralytix, Inc., a privately held company, announced that it had received a grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH), for the clinical development of bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella. The project address a significant public health issue, as it is expected to help reduce the burden of disease caused by Shigella.

Global Bacteriophage Therapy Market– Impact of Coronavirus (COVID-19) Pandemic

• The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
• COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
• The players operating in the global bacteriophage therapy market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include the supply of raw materials for manufacturing drug formulations due to irregularities in transportation facilities. Moreover, distributors of products are experiencing irregular demand for products from retailers due to an increasing patient population suffering from COVID-19 and other life-threatening disorders.
• The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs, and other organizations that support drug development shifted to remote-working environments.

Global Bacteriophage Therapy Market: Key Developments

• On February 22, 2025, BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced positive results from Part 1 of the Phase 1b/2a trial evaluating the company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (CF).
• In May 2025, Intralytix, Inc., a privately held company, announced that it had received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product VRELysin, a bacteriophage preparation to manage colonization of vancomycin-resistant Enterococcus (VRE) in the human gut. Under this IND, continuous, randomized, double-blind Phase 1/2a clinical trials will be performed to assess the safety and efficacy of VRELysin in decolonizing the gastrointestinal tract.
• In June 2025, Intralytix, Inc., a privately held company, announced that it had received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Food and Agriculture (NIFA), an agency of the U.S. Department of Agriculture (USDA), for the development of a phage biocontrol solution for Vibrio parahaemolyticus in various food products, including seafood. The project will focus on developing a phage cocktail for use as a non-chemical and environmentally friendly food safety mitigation strategy in various food products.

Browse 44 Market Data Tables and 45 Figures spread through 180 Pages and in-depth TOC on “Global Bacteriophage Therapy Market”- Forecast to 2032, Global Bacteriophage Therapy Market, By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Others), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Other, By Route of Administration (Oral, Topical, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/bacteriophages-therapy-market-2752

Key Takeaways of the Global Surgical Equipment Market:

• The global bacteriophage therapy market is expected to exhibit a CAGR of 3.7% during the forecast period, owing to increasing research and development activities by key market players to expand their product portfolio. For instance, in February 2025, Locus Biosciences, a clinical-stage biotechnology company, announced the completion of its Phase 1b clinical trial of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage (crPhage) precision medicine product targeting Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs).
• Among targeted bacteria, the escherichia coli segment is expected to hold a dominant position in the global bacteriophage therapy market during the forecast period, and this is attributed to the increasing research and development activities by key market players. For instance, on August 1, 2025, Intralytix, Inc. announced that the clinical trial “A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia coli (AIEC) in Patients with Inactive Crohn’s Disease (CD) will begin enrolling at the Johns Hopkins University (JHU) at various locations throughout the Baltimore metro area in Maryland (USA). The bacteriophage preparation EcoActive targets adherent invasive E. coli (AIEC), a pathogen increasingly implicated in the pathogenesis of Crohn's disease.
• Among region, North America is expected to be the dominant region in the global bacteriophage therapy market, owing to the key players focus on organic strategies such as product approval by regulatory authorities to expand their product portfolio. For instance, in October 2025, Intralytix, Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product ShigActive, a bacteriophage preparation to manage Shigella infections in humans. Under this IND, continuous, randomized, double-blind Phase 1/2a clinical trials will be performed to assess the safety and efficacy of ShigActive in preventing or reducing the severity of human illness due to Shigella infections.
• Major players operating in the global bacteriophage therapy market are Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Enbiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, OPTIPHARM Co., Ltd.